News for Denali Therapeutics Inc. (DNLI)

Wall Street showed mixed performance on Wednesday, April 2, 2025, as investors anxiously awaited President Donald Trump's

U.S. stock markets displayed cautious trading on Wednesday, April 2, 2025, as investors braced for President Trump's highly anticipated tariff announcement

Gene therapy is a medical approach that entails changing or modifying genes to treat or prevent disease.

Despite past failures, Denali's extensive pipeline and solid financial runway make it a compelling buy at current low stock prices. Learn more on DNLI stock here.

Market News Alerts Reports: NeuroSense Therapeutics Ltd. (NASDAQ: NRSN)* has announced significant progress toward the early commercialization of PrimeC in Can

PESG Research releases a new report covering NeuroSense Therapeutics (NASDAQ: NRSN)* and its recent developments: In a medical landscape hungry for innovation,

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we are going to take a look at where Denali Therapeutics Inc.

Denali Therapeutics Inc (DNLI) showcases a robust pipeline with innovative blood-brain barrier platform technologies.Despite being in the clinical stage, DNLI

On February 27, 2025, Denali Therapeutics Inc (DNLI) released its financial results for the fourth quarter and full year ending December 31, 2024. The company h

SOUTH SAN FRANCISCO, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. ( DNLI) today reported financial results for the fourth quarter and ye

**media[552840]**

On December 31, 2024, Baillie Gifford (Trades, Portfolio) made a significant move in its investment portfolio by reducing its position in Denali Therapeutics In

**media[534402]**

Summary Denali Therapeutics Inc (DNLI) has released promising long-term data from its Phase 1/2 study of tividenofusp alfa (DNL310) for treating Hunter syndrome

Denali Therapeutics Inc (DNLI), a biopharmaceutical company based in South San Francisco, announced significant milestones for 2025, including the FDA Breakthro

FDA Breakthrough Therapy Designation received for tividenofusp alfa for Hunter syndrome (MPS II); on track to submit biologics license application (BLA) in earl

Denali Therapeutics Inc.'s stock remains stable despite trial setback in ALS. BLA filing for MPS II treatment on track. Click for my DNLI stock update.

SOUTH SAN FRANCISCO, CA, Tenvie Therapeutics launched with $200 million in funding led by ARCH Venture Partners, F-Prime Capital, Mubadala Capital.

Denali Therapeutics Inc (DNLI) has released topline results from the Phase 2/3 HEALEY ALS Platform Trial, evaluating the eIF2B agonist DNL343 for the treatment